Japanese Journal of Clinical Oncology 31:357-358 (2001)
© 2001 Foundation for Promotion of Cancer Research
Editorial |
Cancer Chemoprevention as Adjuvant Therapy for Hepatocellular Carcinoma
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors around the world. In Japan, the number of patients who die from HCC has been increasing annually and reached about 33 000 in 1998. At present, HCC is the third most common cause of cancer death among males and the fourth among females. Imaging diagnosis and assessment of tumor markers indicating small mass lesions in the liver have progressed in recent years. As a result, screening programs that use such diagnostic modalities have facilitated the early detection of HCC in patients with chronic liver disease and has increased the number of candidates for effective local treatments such as hepatic resection and percutaneous ablation therapy. However, very few patients undergoing such local treatments can be cured and the overall results of these treatments are still unsatisfactory, mostly because of post-therapeutic recurrence.
FOOTNOTES
REFERENCES